Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene receives NICE backing for Abraxane in pancreatic cancer

Celgene receives NICE backing for Abraxane in pancreatic cancer

7th August 2017

Celgene has announced that its drug Abraxane has been recommended for routine NHS use as a first-line treatment for advanced pancreatic cancer.

The nab-paclitaxel therapy has been endorsed by the National Institute for Health and Care Excellence (NICE) for use in combination with gemcitabine as a first-line treatment for metastatic pancreatic ductal adenocarcinoma.

Phase III clinical trial results have showed that Abraxane, when administered together with gemcitabine, improved median survival rates of the disease by 1.8 months compared to gemcitabine alone.

This treatment option will now be made available for patients on the NHS in England and Wales, and represents an important new treatment option for a condition associated with a persistently low rate of long-term survival.

Remo Gujer, general manager for Celgene in the UK and Ireland, said: "We are pleased to have been able to work with NICE throughout this process to help ensure that this treatment combination becomes accessible via the NHS to eligible patients with metastatic pancreatic cancer across England."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801838660-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.